Form 4: Rhythm Pharmaceuticals Director Exercises Options and Sells Over 65,000 Shares in Pre-Planned Transactions

A director at Rhythm Pharmaceuticals, David W.J. McGirr, exercised stock options and subsequently sold a significant number of common shares, reducing his direct beneficial ownership.

Summary

• David W.J. McGirr, a Director at Rhythm Pharmaceuticals, Inc. (RYTM), executed transactions on June 3, 2025, under a Rule 10b5-1 plan adopted on February 28, 2025.
• Mr. McGirr acquired 65,431 shares of common stock by exercising stock options at an exercise price of $4.59 per share.
• Immediately following the option exercise, Mr. McGirr disposed of 55,558 shares of common stock at a weighted average price of $65.1464 per share, with prices ranging from $64.59 to $65.58.
• Additionally, he sold another 9,873 shares of common stock at a weighted average price of $65.6427 per share, with prices ranging from $65.59 to $65.81.
• These sales resulted in a total disposition of 65,431 shares, matching the number of shares acquired through the option exercise.
• Following these reported transactions, Mr. McGirr's direct beneficial ownership of Rhythm Pharmaceuticals common stock stands at 3,000 shares.
• The stock option exercised was fully vested and had an expiration date of November 16, 2025.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative. While the transactions were pre-planned under a 10b5-1 plan and represent profit-taking, the director sold all shares acquired from the option exercise and significantly reduced their overall direct beneficial ownership to a minimal amount, which can sometimes be viewed unfavorably by investors.

Positives

• The director realized a substantial profit from the transactions, as the shares were sold at prices significantly higher than the option exercise price of $4.59.
• The transactions were conducted under a pre-arranged Rule 10b5-1 plan, indicating a planned and transparent disposition of shares rather than an immediate reaction to market conditions.

Negatives

• The director sold a substantial number of shares (65,431), effectively liquidating all shares acquired from the option exercise and reducing his direct beneficial ownership to a relatively small holding of 3,000 shares.
• Significant insider selling, even if pre-planned, can sometimes be interpreted by the market as a lack of strong conviction in the company's future growth by an insider.

Future Outlook

This Form 4 filing is a disclosure of insider transactions and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a standard disclosure of insider trading activity for a publicly traded biotechnology company. Such transactions are common for executives and directors managing their personal portfolios, especially when stock options vest and approach expiration.

Corporate Governance

Related Party Transactions

• The reported transactions involve a director of Rhythm Pharmaceuticals, Inc. and are considered insider transactions, which are a form of related party dealing in the context of securities law.

Stakeholder Impact

• Shareholders: May interpret the significant sale by a director, even if pre-planned, as a signal regarding the director's long-term confidence in the company, potentially influencing investor sentiment.

Key Dates

Keywords

Rhythm Pharmaceuticals, RYTM, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, 10b5-1 Plan, Director Transactions, Common Stock